Trial Profile
A retrospective trial evaluating use, efficacy, and tolerability of 20% subcutaneous immunoglobulin in patients with primary immunodeficiency.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2016 New trial record
- 25 May 2016 Results published in the Annals of Allergy, Asthma and Immunology